MDT

96.16

+0.02%↑

137.38

+0.87%↑

VEEV

219.47

-1.63%↓

HQY

91.67

+0.17%↑

PHR.US

16.25

-3.85%↓

MDT

96.16

+0.02%↑

137.38

+0.87%↑

VEEV

219.47

-1.63%↓

HQY

91.67

+0.17%↑

PHR.US

16.25

-3.85%↓

MDT

96.16

+0.02%↑

137.38

+0.87%↑

VEEV

219.47

-1.63%↓

HQY

91.67

+0.17%↑

PHR.US

16.25

-3.85%↓

MDT

96.16

+0.02%↑

137.38

+0.87%↑

VEEV

219.47

-1.63%↓

HQY

91.67

+0.17%↑

PHR.US

16.25

-3.85%↓

MDT

96.16

+0.02%↑

137.38

+0.87%↑

VEEV

219.47

-1.63%↓

HQY

91.67

+0.17%↑

PHR.US

16.25

-3.85%↓

Strona główna・Stock List・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Open

SectorHealthcare

36.88 -1.34

Buy Sell

Overview

Share price change

24h

Current

Min

36.3

Max

37.11

Key metrics
By Trading Economics
Income	11M 51M
Sales	39M 239M
P/E Sector Avg	11.959 88.032
EPS	1.08
Profit margin	21.242
Employees	268
EBITDA	14M 73M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+16.52% upside

Market Stats
By TradingEconomics
Market Cap	496M 2.2B
Previous open	38.22
Previous close	36.88

News Sentiment

By Acuity

50%

141 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

29.8 / N/A Support & Resistance

Harmony Biosciences Holdings Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

31 gru 2025, 22:20 UTC

Major Market Movers

Outlook Therapeutics Shares Fall After Another FDA Rejection of Macular Degeneration Drug

31 gru 2025, 17:31 UTC

Major Market Movers

OwlTing Climbs on Launch of $10 Million Stock-Buyback Program

31 gru 2025, 16:30 UTC

Major Market Movers

Trump Media Gains on Plan to Distribute Digital Tokens to Shareholders

31 gru 2025, 15:19 UTC

Major Market Movers

Axsome Shares Climb on FDA Fast‑Track for Alzheimer's Drug, Backing for Narcolepsy Filing

31 gru 2025, 15:17 UTC

Major Market Movers

Nike Shares Rise After CEO Hill Buys $1 Million of Shares

31 gru 2025, 14:37 UTC

Major Market Movers

Corcept Shares Fall as FDA Requires More Evidence for Hypercortisolism Drug Application

1 sty 2026, 23:35 UTC

Market Talk

Gold Rises Amid Geopolitical Risks -- Market Talk

1 sty 2026, 21:29 UTC

Acquisitions, Mergers, Takeovers

BlueScope: Transaction Completed on Terms Agreed When Deal Announced on Nov 13

1 sty 2026, 21:29 UTC

Acquisitions, Mergers, Takeovers

BlueScope Sold Stake in JV to Tata Steel

1 sty 2026, 21:28 UTC

Acquisitions, Mergers, Takeovers

BlueScope Steel Says Sale of Stake in Tata BlueScope Steel Completed on Dec 31

1 sty 2026, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

1 sty 2026, 09:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

31 gru 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

31 gru 2025, 21:13 UTC

Acquisitions, Mergers, Takeovers

10 People to Watch in Wealth Management in 2026 -- Barrons.com

31 gru 2025, 20:40 UTC

Market Talk

Dollar Posting Its Worst Year Since 2017 -- Market Talk

31 gru 2025, 20:22 UTC

Market Talk

Oil Posts Loss in a Year Marked By Plentiful Supply -- Market Talk

31 gru 2025, 19:50 UTC

Market Talk

U.S. Natural Gas Futures Sink on Weather Outlook -- Market Talk

31 gru 2025, 19:31 UTC

Market Talk

Precious Metals Cap Off Record Runs -- Market Talk

31 gru 2025, 18:50 UTC

Market Talk

Global Equities Roundup: Market Talk

31 gru 2025, 18:50 UTC

Market Talk

Canadian Gold Miners Enjoy a Bumper Year in 2025 -- Market Talk

31 gru 2025, 17:17 UTC

Market Talk

U.S. Natural Gas Inventories Fall Less Than Expected -- Market Talk

31 gru 2025, 17:16 UTC

Major Market Movers

OwlTing Climbs on Launch of $10M Stock-Buyback Program

31 gru 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

31 gru 2025, 17:00 UTC

Acquisitions, Mergers, Takeovers

Nvidia Is Getting Creative as Options to Use Its Cash Flood Narrow -- Heard on the Street -- WSJ

31 gru 2025, 15:57 UTC

Acquisitions, Mergers, Takeovers

Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval -- Barrons.com

31 gru 2025, 15:54 UTC

Market Talk

Layoff Data Supports Dollar at End of Losing Year -- Market Talk

31 gru 2025, 15:02 UTC

Major Market Movers

Nike Shares Rise After CEO Hill Buys $1M of Shares

31 gru 2025, 14:40 UTC

Acquisitions, Mergers, Takeovers

Nike CEO Buys $1 Million of Stock as Insiders Bet on a Turnaround -- Barrons.com

31 gru 2025, 14:20 UTC

Market Talk

Crude Futures On Track to End the Year With Losses -- Market Talk

31 gru 2025, 13:46 UTC

Market Talk

U.S. Natural Gas Falls on Milder Weather Outlook -- Market Talk

Peer Comparison

Price change

Harmony Biosciences Holdings Inc Forecast

Price Target

By TipRanks

16.52% upside

12 Months Forecast

Average 43.6 USD 16.52%

High 55 USD

Low 32 USD

Based on 6 Wall Street analysts offering 12 month price targets forHarmony Biosciences Holdings Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

6 ratings

Buy

Hold

Sell

Based on 6 analysts giving stock ratings to Harmony Biosciences Holdings Inc - Dist in the past 3 months.

Technical Score

By Trading Central

29.8 / N/ASupport & Resistance

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

141 / 374 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.